Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
about
Cefepime versus other beta-lactam antibiotics for the treatment of infections in non-neutropenic patientsCefepime versus other beta-lactam antibiotics for the treatment of infections in non-neutropenic patientsCefepimeRapid high-performance liquid chromatographic determination of cefepime in human plasma.Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centersFourth generation cephalosporins in the antimicrobial chemotherapy of surgical infections.Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosingPharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.Decision analysis modelling of costs and outcomes following cefepime monotherapy in CanadaCefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review.Emerging drugs for acute bacterial meningitis.Cefepime- Induced Non-Convulsive Status Epilepticus (NCSE).Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: case report, pharmacokinetic modeling, and review of the literature.Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer.Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study.Acute Generalized Exanthematous Pustulosis Induced by Cefepime: A Case Report.Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.Stevens-Johnson syndrome caused by cefepime?Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.Cefepime versus ceftazidime in the treatment of lower respiratory tract infections.Cefepime versus ceftazidime for treatment of pneumonia.
P2860
Q24200940-6622970F-25C4-4210-A3BA-0AF704FA4AABQ24242482-69DA2CB7-52F5-43CA-A7FD-F3CDC2997419Q29040262-37AC8A67-0FCF-4CE0-B54D-39C657DFBA67Q30739885-5B7FA3F0-F7D5-4557-BAFD-34CADCC8DA1BQ33177765-65D02372-DAF9-4CCE-AC23-445048C2C4B1Q33840080-CB72AAB2-B996-4994-A483-981C8D0CFCEDQ33977939-0F27028D-A6D8-4C75-92D3-4744F7A88D2EQ33983364-8B02D557-1819-47DF-B2DB-EAFD283D0BD4Q35114789-9932823B-AB7B-4EC4-B50A-9607E7B6BBB8Q35137735-2F997844-CFBD-4E43-804E-32567CC069B9Q35891256-83243975-5E7C-4DFB-9CF9-249C4D965A8BQ36545084-0E6E5014-F5BB-4A90-9C05-7C7974E4E1FDQ37558543-D9FB4E80-F3D4-481A-A1AD-74305320ED0FQ37642767-91C32355-F303-41D5-B65B-6BA3CE15E5B6Q38232834-9A093538-25D1-48DD-A59C-50B0EEF9A825Q40274934-B7627081-4A5D-4394-B011-66FA9B191B43Q40315393-6719A92D-2A49-4FA9-BA37-9293485C5B76Q40352823-58C68FAE-79FB-4E4B-A8CB-B914D522C36AQ40512932-99FFF3B4-53E9-478F-92CF-B7A9BC725734Q40591496-DE1254D0-08D9-4957-9479-06BBBE588809Q40624011-ADB0185A-3FA1-45EF-B428-7610206E3322Q41547219-E170D9AC-B19F-4A93-AD32-80AB1ADBE794Q41700892-C096B0C2-8FC2-4001-B577-C0ABF3825D2DQ41991766-E8900B81-2A20-4210-A262-CBD07771FB5CQ42080826-CF1B1F75-DA5F-4966-9177-51BA20FC9237Q43153489-355C508D-2FE8-4D5C-92B5-45166BDAC61AQ43803069-3C96793E-E50D-4C5B-8073-362C11C63350Q44287991-47A3F507-4857-408F-94DB-DA01DE1C0A61Q44533712-1C3836C3-FF30-4AD3-833B-8A3E7007D3F9Q44784514-F736E6EE-240F-4169-8B88-2455075A7C21
P2860
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Cefepime. A review of its anti ...... roperties and therapeutic use.
@en
type
label
Cefepime. A review of its anti ...... roperties and therapeutic use.
@en
prefLabel
Cefepime. A review of its anti ...... roperties and therapeutic use.
@en
P1433
P1476
Cefepime. A review of its anti ...... roperties and therapeutic use.
@en
P2093
H M Bryson
L B Barradell
P304
P356
10.2165/00003495-199447030-00007
P577
1994-03-01T00:00:00Z
P6179
1051058903